Antibodies that modulate immunity to drug resistant and latent MTB infections
The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.
1. A method for treating infection of drug-resistant Mycobacterium tuberculosis (MTB) in a mammal comprising:
providing an immunological composition containing an antibody that binds to an epitope of an antigen of MTB, wherein the antigen is obtained or derived from MTB that has been killed by exposure to a chemical and/or physical treatment wherein,
the epitope is not immunologically available prior to the chemical and/or physical treatment,
the antigen comprises peptidoglycan, mycolic acid, an MTB heat-shock protein, or lipoarabinomannan, and
the chemical and/or physical treatment comprises exposure to about 70% ethanol or about 2% glutaraldehyde, activated with sodium biocarbonate; and
administering the composition to the mammal,
wherein the composition induces the immunological system of the mammal to promote phagocytosis and killing MTB infected cells.
2. The method of claim 1 , wherein the phagocytosis and killing is enhanced in the presence of the composition as compared to the phagocytosis and killing of mycobacteria in the absence of the composition.
3. The method of claim 1 , wherein the composition comprises polyclonal antibodies, monoclonal antibodies, or both polyclonal and monoclonal antibodies.
4. The method of claim 2 , wherein the epitope is chemically or physically altered as compared with the naturally occurring epitope.
5. The method of claim 1 , wherein the immunological composition is an adjunctive therapy in combination with administration of an antibiotic.
6. The method of claim 1 , wherein administration of the immunological composition clears MTB from the blood of the mammal.
7. The method of claim 1 , wherein the immunological composition modulates immunity to drug-resistant MTB.
8. The method of claim 1 , wherein the immunological composition is administered at a therapeutically-effective dose.
9. A method of treating an infection in a mammal caused by a Mycobacterium tuberculosis (MTB) microorganism comprising:
administering a composition to the mammal, wherein the composition contains an antibody that binds to an epitope of an MTB antigen, wherein:
the epitope is immunologically exposed only after the MTB microorganism is exposed to a chemical and/or physical treatment sufficient to kill the microorganism;
the MTB antigen comprises peptidoglycan, mycolic acid, an MTB heat-shock protein or lipoarabinomannan; and
the chemical and/or physical treatment comprises exposure of the MTB microorganism to about 70% ethanol or about 2% glutaraldehyde, activated with sodium bicarbonate, in a manner sufficient to kill the MTB microorganism;
inducing the immunological system of the mammal to promote opsonophagocytosis of cells infected with the MTB microorganism.
10. A method of treating an infection caused by a Mycobacterium tuberculosis (MTB) microorganism comprising:
exposing MTB microorganisms to a chemical and/or physical treatment which would be sufficient to kill MTB microorganisms, wherein the chemical and/or physical treatment comprises exposure to about 70% ethanol or about 2% glutaraldehyde, activated with sodium bicarbonate, that immunologically exposes an MTB epitope that is not immunologically exposed with untreated MTB microorganisms;
generating antibodies to the exposed MTB epitope; and
administering the antibodies generated to a mammal with an active or suspected MTB infection, wherein administration induces a humoral immunological response that promotes opsonophagocytosis of cells infected with MTB microorganisms.
11. The method of claim 10 , wherein the chemical and/or physical treatment further comprises additional exposure to heat, alcohol, glutaraldehyde and/or sonication.
12. The method of claim 10 , wherein the MTB epitope is located on a peptidoglycan, a mycolic acid, a heat-shock protein, or a lipoarabinomannan glycolipid of MTB.
13. The method of claim 9 , wherein administration of the immunological composition clears MTB from the blood of the mammal.
14. The method of claim 9 , wherein the composition modulates immunity to drug-resistant MTB.
15. The method of claim 9 , wherein the composition is administered at a therapeutically-effective dose.
16. The method of claim 10 , wherein antibodies clear MTB from the blood of the mammal.
17. The method of claim 10 , wherein the antibodies modulate immunity to drug-resistant MTB.
18. The method of claim 10 , wherein the antibodies are administered at a therapeutically-effective dose.